International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0
|
作者：
Matveev, V. B. [1 ]
Khalmurzaev, O. A. [1 ]
Evsyukova, O., I [1 ]
机构：
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
来源：
ONKOUROLOGIYA | 2020年 / 16卷 / 04期
关键词：
prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;
D O I：
10.17650/1726-9776-2020-16-4-197-206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [31] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
  • [32] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [33] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [34] Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective
    Matsumoto, Takashi
    Shiota, Masaki
    Blas, Leandro
    Eto, Masatoshi
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2389 - 2397
  • [35] CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.
    Chen, Gang
    Karzai, Fatima
    Madan, Ravi Amrit
    Cordes, Lisa M.
    Bilusic, Marijo
    Owens, Helen
    Hankin, Amy
    Williams, Monique
    Couvillon, Anna
    Gulley, James L.
    Dahut, William L.
    Thomas, Anish
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer
    Maughan, Benjamin L.
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (12) : 1625 - 1632
  • [37] Ectopic Cushing syndrome in metastatic castration-resistant prostate cancer: A case report and review of literature
    Andrikopoulou, Angeliki
    Goga, Kristiana
    Stefanaki, Katerina
    Paschou, Stavroula A.
    Athanasopoulos, Stavros
    Zagouri, Flora
    Dimopoulos, Meletios-Athanasios
    ONCOLOGY LETTERS, 2024, 28 (03)
  • [38] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2020, 15 (06) : 791 - 799
  • [39] Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Al-Salama, Zaina T.
    DRUGS, 2019, 79 (14) : 1591 - 1598
  • [40] Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Zaina T. Al-Salama
    Drugs, 2019, 79 : 1591 - 1598
12345